> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Atrium Begins Dosing In Corventis, A Trial Of An RNA Drug For Rare Heart Disease PRKAG2
- URL: https://www.bullished.co/atrium-begins-dosing-in-corventis-a-trial-of-an-rna-drug-for-rare-heart-disease-prkag2-6636cc5f/
- Published: 2026-10-27T13:05:59.000Z
- Updated: 2026-10-28T15:58:39.000Z
- Description: The San Diego company's lead RNA drug, ATR 1072, enters a trial of about 37 participants, with first proof-of-concept data expected in the second half of 2027.
- Author: Matteo Parrino
- Tags: SEC Filings, RNA, Industry: Healthcare

[Atrium Therapeutics](https://www.bullished.co/tag/rna/), a San Diego biopharmaceutical company developing RNA drugs targeted to the heart, said Tuesday it has [dosed the first patient](https://www.sec.gov/Archives/edgar/data/0002093101/000119312526432949/d134020d8k.htm?ref=bullished.co) in Corventis, a Phase 1/2 trial of its lead candidate, ATR 1072, for PRKAG2 syndrome. The company calls it the first interventional trial for people with the rare genetic heart disease, and it expects initial proof-of-concept data in the second half of 2027.

## Inside the Corventis design

Corventis is an open-label, multicenter study that will [enroll approximately 37 participants](https://www.sec.gov/Archives/edgar/data/0002093101/000119312526432949/d134020dex991.htm?ref=bullished.co) in two parts. Part A uses multiple ascending dose cohorts to characterize safety and support dose selection. Part B is a single-arm expansion at the recommended Phase 2 dose, meant to look at efficacy trends in cardiac structure and function.

The main goal is the incidence of treatment-emergent adverse events. Secondary and exploratory measures include PRKAG2 mRNA reduction, siRNA tissue concentrations and plasma pharmacokinetics.

CEO Kathleen Gallagher called the dosing a milestone and said it is the first trial evaluating a potential treatment for the underlying cause of the disease.

## A disease managed, not treated

PRKAG2 syndrome is a rare, progressive, life-threatening cardiomyopathy with no approved therapies. Mutations overactivate an enzyme called AMPK, causing glycogen to build up in heart muscle, which may lead to heart failure and sudden cardiac death. The company cites literature estimates of at least [1,000 to 2,000 people](https://finance.yahoo.com/healthcare/articles/atrium-therapeutics-doses-first-patient-103000321.html?ref=bullished.co) with it in the US.

Michael Nassif, a heart failure cardiologist at Saint Luke's Mid America Heart Institute, said the best doctors can offer now is "a pacemaker, a defibrillator, and our best efforts to prevent life-threatening arrhythmias."

## An antibody-delivered RNA drug

ATR 1072 is an antibody oligonucleotide conjugate built on Atrium's targeted RNA delivery platform. It uses small interfering RNA to silence mutant PRKAG2 messenger RNA, with the aim of normalizing AMPK activity and improving heart function, according to the [company's release](https://finance.yahoo.com/healthcare/articles/atrium-therapeutics-doses-first-patient-103000321.html?ref=bullished.co).

The platform was designed at Avidity Biosciences, the company said. Atrium's pipeline also includes ATR 1086 for PLN cardiomyopathy and two undisclosed research targets in rare cardiomyopathies.

Atrium's own risk language flags enrollment as a hurdle given how rare the diseases it targets are, with the first data due in the second half of 2027.

Learn

- [Item 8.01: other events →](https://www.bullished.co/learn/8-k-items-explained/#item-801-other-events)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Atrium Therapeutics, Inc. (RNA)](https://www.sec.gov/Archives/edgar/data/0002093101/000119312526432949/d134020d8k.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit d134020dex991.htm — Atrium Therapeutics, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0002093101/000119312526432949/d134020dex991.htm?ref=bullished.co) — SEC EDGAR
- [Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome](https://finance.yahoo.com/healthcare/articles/atrium-therapeutics-doses-first-patient-103000321.html?ref=bullished.co) — Yahoo Finance

### More on Atrium Therapeutics

- [Atrium Therapeutics Amends 8-K: 21,571,507 Shares Will Be Outstanding After Private Placement](https://www.bullished.co/atrium-therapeutics-amends-8-k-21-571-507-shares-will-be-outstanding-after-private-30e393ae/)
- [Atrium Therapeutics Agrees To Sell About $50 Million Of Stock At $7.93, Says Cash Now Lasts Through 2028](https://www.bullished.co/atrium-therapeutics-agrees-to-sell-about-50-million-of-stock-at-7-93-says-cash-now-lasts-864596d9/)

[All Atrium Therapeutics (RNA) coverage →](https://www.bullished.co/tag/rna/)